FAS and ovarian cancer: Evaluating whether TCR1045/Fas-4-1BBtm T cells control progressive ovarian cancer more effectively than TCR1045 T cells, we used an established treatment protocol that previously revealed TCR1045 T cells prolong survival of ID8VEGF tumor-bearing mice.10 Briefly, ID8VEGF tumor-bearing mice were treated with a single dose of cyclophosphamide ≥6 hours prior to T cell transfer, and then received 1×107 engineered T cells and 5×107 irradiated splenocytes pulsed with MSLN404-416 peptide every 14 days (lymphodepletion occurred only before the first T cell transfer).